Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.
A total of 7,272 unique patient clinical isolates were collected from 71 U.S. medical centers from patients with urinary tract infections in 2012 to 2014 and tested for susceptibility to ceftazidime-avibactam and comparators by broth microdilution methods. Ceftazidime-avibactam inhibited >99.9% of all Enterobacteriaceae at the susceptible breakpoint of ≤8 μg/ml (there were only three nonsusceptible strains). Ceftazidime-avibactam was also active against Pseudomonas aeruginosa isolates (MIC50, 2 μg/ml; MIC90, 4 μg/ml; 97.7% susceptible), including many isolates not susceptible to meropenem, ceftazidime, and/or piperacillin-tazobactam.
JMI Laboratories, North Liberty, Iowa, USA helio-sader@jmilabs.com.
Helio S
HS
Sader
JMI Laboratories, North Liberty, Iowa, USA.
Mariana
M
Castanheira
JMI Laboratories, North Liberty, Iowa, USA.
Robert K
RK
Flamm
JMI Laboratories, North Liberty, Iowa, USA.
Ronald N
RN
Jones
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D053961:Azabicyclo Compounds / Q000627:therapeutic use*; D002442:Ceftazidime / Q000627:therapeutic use*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000235:genetics / Q000472:pathogenicity; D006801:Humans; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity; D014552:Urinary Tract Infections / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; C543519:avibactam; D002442:Ceftazidime